Isolated Components From Spider Venom Targeting Human Glioblastoma Cells and Its Potential Combined Therapy With Rapamycin.
animal venom
cancer therapy
cytotoxicity
glioblastoma
mTOR
rapamycin
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
08
2021
accepted:
28
01
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Glioblastomas (GBs) are responsible for a higher mortality rate among gliomas, corresponding to more than 50% of them and representing a challenge in terms of therapy and prognosis. Peptide-based antineoplastic therapy is a vast and promising field, and these molecules are one of the main classes present in spider venoms. Recently, our research group demonstrated the cytotoxic effects of
Identifiants
pubmed: 35359607
doi: 10.3389/fmolb.2022.752668
pii: 752668
pmc: PMC8964069
doi:
Types de publication
Journal Article
Langues
eng
Pagination
752668Informations de copyright
Copyright © 2022 Caballero, Barreto, Bonfanti, Munhoz, Rocha e Silva, Sutti, Verinaud, Pinheiro de Mato, Lanfredi and Rapôso.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Brain Res. 2013 Feb 7;1495:37-51
pubmed: 23261661
Gene. 2016 Jan 10;575(2 Pt 1):187-90
pubmed: 26341051
Sci Rep. 2020 Apr 3;10(1):5876
pubmed: 32246025
Toxicon. 2020 Oct 15;185:76-90
pubmed: 32649934
Cancer Genet. 2012 Dec;205(12):613-21
pubmed: 23238284
Cancer Treat Rev. 2019 Nov;80:101896
pubmed: 31541850
Oncotarget. 2016 May 31;7(22):33440-50
pubmed: 26967052
JAMA. 2005 Feb 2;293(5):557-64
pubmed: 15687310
Nat Commun. 2017 May 12;8:15223
pubmed: 28497778
J Venom Anim Toxins Incl Trop Dis. 2019 Jun 03;25:e146318
pubmed: 31210759
DNA Cell Biol. 2007 Jul;26(7):485-9
pubmed: 17630852
PLoS Med. 2008 Jan 22;5(1):e8
pubmed: 18215105
Dis Markers. 2018 Dec 18;2018:9230479
pubmed: 30662577
Cell Mol Neurobiol. 2005 Aug;25(5):929-41
pubmed: 16133944
Clin Adv Hematol Oncol. 2012 Apr;10(4):240-6
pubmed: 22706484
Br J Pharmacol. 2020 Mar;177(6):1409-1423
pubmed: 31368509
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Nat Rev Dis Primers. 2015 Jul 16;1:15017
pubmed: 27188790
Cell Cycle. 2009 Apr 1;8(7):1026-9
pubmed: 19270529
BMC Cancer. 2008 Oct 08;8:291
pubmed: 18840301
J Cell Physiol. 2019 Feb;234(2):1398-1415
pubmed: 30078202
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Clin Microbiol Rev. 2006 Jul;19(3):491-511
pubmed: 16847082
Microsc Res Tech. 2009 Apr;72(4):310-6
pubmed: 19009596
Cancer Cell Int. 2020 Dec 17;20(1):576
pubmed: 33327966
J Clin Transl Res. 2017 May 24;3(2):233-249
pubmed: 30873475
BMC Genomics. 2014 Mar 05;15:177
pubmed: 24593665
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Curr Gene Ther. 2011 Jun;11(3):155-80
pubmed: 21453286
J Neurooncol. 2010 Jan;96(2):219-30
pubmed: 19562254
Cancer Cell Int. 2005 May 10;5(1):13
pubmed: 15885136
Curr Oncol. 2015 Aug;22(4):e273-81
pubmed: 26300678
Mol Biol (Mosk). 2016 Jan-Feb;50(1):115-27
pubmed: 27028817
Regul Toxicol Pharmacol. 2013 Feb;65(1):119-25
pubmed: 23200793
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931